Development and In-Vitro Evaluation of Sitagliptin Fast Dissolving Tablets for Enhanced Oral Bioavailability
International Journal of Drug Delivery Technology · 25.04.2026 · 16 (20s)
DOI: 10.25258/ijddt.16.20s.63 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 25.04.2026. Verfasst von Abhishek Mishra und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both. The present study aimed to formulate and evaluate fast dissolving tablets (FDTs) of Sitagliptin in order to improve drug dissolution, patient compliance, and oral bioavailability. Fast dissolving tablets were prepared by the direct compression method using different concentrations of superdisintegrants such as croscarmellose sodium (CCS) and sodium starch glycolate (SSG). Six formulations (S1–S6) were developed and evaluated for pre-compression and post-compression parameters. Preformulation studies indicated that Sitagliptin possessed suitable physicochemical properties with bulk density 0.46 g/ml, tapped density 0.54 g/ml, Carr's index 14.81, Hausner's ratio 1.17, and angle of repose 28.6°, confirming good flow characteristics. FTIR compatibility studies revealed no significant interaction between the drug and excipients. The prepared tablets were evaluated for weight variation, hardness, friability, thickness, disintegration time, wetting time, water absorption ratio, drug content, and in vitro dissolution. Among the developed formulations, S3 showed the best performance, exhibiting rapid disintegration (21 sec), high water absorption ratio (90%), and drug content of 100.2%. The dissolution study demonstrated that formulation S3 released 65.3% of drug within 5 minutes, indicating rapid drug release. In vitro permeability studies using the Caco-2 cell model showed improved apparent permeability for the optimized formulation (Papp 4.21 ×10⁻⁶ cm/s) compared with the marketed tablet (2.85 ×10⁻⁶ cm/s). Stability studies conducted for three months showed no significant change in physical appearance, drug content, disintegration time, or dissolution profile. The results indicate that the developed Sitagliptin fast dissolving tablets provide rapid drug release and enhanced permeability, suggesting improved oral bioavailability and better patient compliance compared to conventional tablet formulations.
Zitieren
APA
Mishra, A., Sonker, S., Yogi, B., & Gupta, S. K. (2026). Development and In-Vitro Evaluation of Sitagliptin Fast Dissolving Tablets for Enhanced Oral Bioavailability. International Journal of Drug Delivery Technology, 16(20s). https://doi.org/10.25258/ijddt.16.20s.63
Vancouver
Mishra A, Sonker S, Yogi B, Gupta SK. Development and In-Vitro Evaluation of Sitagliptin Fast Dissolving Tablets for Enhanced Oral Bioavailability. International Journal of Drug Delivery Technology. 2026;16(20s). doi:10.25258/ijddt.16.20s.63
BibTeX
@article{Mishra2026,
author = {Mishra, Abhishek and Sonker, Shilpi and Yogi, Bhumika and Gupta, Sujeet Kumar},
title = {Development and In-Vitro Evaluation of Sitagliptin Fast Dissolving Tablets for Enhanced Oral Bioavailability},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {20s},
doi = {10.25258/ijddt.16.20s.63}
}
EUVIMED